Tinlarebant PDUFA date

The PDUFA goal date for Tinlarebant (LBS-008) in Stargardt disease type 1 is 12 Feb 2027, as disclosed by Belite Bio, Inc (BLTE).

PDUFA date
12 Feb 2027
Condition
Stargardt disease type 1

Drug identity checked against registry records

Also recorded as LBS-008

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-02-12DayTinlarebantBelite Bio, Inc · BLTECompany-disclosed PDUFA goal dateAnnounced review targetStargardt disease type 1Open original source
Read source excerpt

U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027

First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026

2027-02-12DayTinlarebantBelite Bio, Inc · BLTECompany-disclosed PDUFA goal dateAnnounced review targetStargardt disease type 1 (STGD1)Open original source
Read source excerpt

New Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Food and Drug Administration (FDA) in August 2026 with Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027

First seen: 13 Nov 2026 · Evidence last checked: 13 Nov 2026